Abnormal unsaturated fatty acid metabolism in cystic fibrosis: Biochemical mechanisms and clinical implications

International Journal of Molecular Sciences

Volumn 15, Issue 9, 2014, Pages 16083-16099

  Seegmiller, Adam C ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cystic fibrosis; Eicosanoids; Fatty acid desaturase; Unsaturated fatty acids

Indexed keywords

5, 8, 11 ICOSATRIENOIC ACID; ACETYL COENZYME A CARBOXYLASE; ACYL COENZYME A DESATURASE; ACYL COENZYME A DESATURASE 1; ARACHIDONIC ACID; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; ELONGASE; ENZYME; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; ICOSAPENTAENOIC ACID; LEUKOTRIENE; LINOLEIC ACID; LINOLEOYL COENZYME A DESATURASE; LIPOXIN; LIVER KINASE B1; PALMITOLEIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHATIDYLCHOLINE; POLYUNSATURATED FATTY ACID; PROSTAGLANDIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRYPSINOGEN; UNCLASSIFIED DRUG; UNSATURATED FATTY ACID; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE REGULATOR GENE; FATTY ACID METABOLISM; FATTY ACID OXIDATION; GENE; HUMAN; LIPID BLOOD LEVEL; LIPID COMPOSITION; MALABSORPTION; NONHUMAN; PANCREAS INSUFFICIENCY; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; BLOOD; GENETICS; METABOLISM; PATHOLOGY;

AMP-ACTIVATED PROTEIN KINASES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FATTY ACID DESATURASES; FATTY ACIDS, UNSATURATED; HUMANS; SIGNAL TRANSDUCTION;

EID: 84908183728     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150916083     Document Type: Review

References (124)

1. Walters, S.; Mehta, A. Epidemiology of cystic fibrosis. In Cystic Fibrosis; Hodson, M., Geddes, D.M., Bush, A., Eds.; Edward Arnold, Ltd.: London, UK, 2007; pp. 21-45.
2. Riordan, J.R.; Rommens, J.M.; Kerem, B.; Alon, N.; Rozmahel, R.; Grzelczak, Z.; Zielenski, J.; Lok, S.; Plavsic, N.; Chou, J.L.; et al. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science 1989, 245, 1066-1073.
3. Kerem, B.; Rommens, J.M.; Buchanan, J.A.; Markiewicz, D.; Cox, T.K.; Chakravarti, A.; Buchwald, M.; Tsui, L.C. Identification of the cystic fibrosis gene: Genetic analysis. Science 1989, 245, 1073-1080.
4. Riordan, J. CFTR function and prospects for therapy. Annu. Rev. Biochem. 2008, 77, 701-726.
5. O'Sullivan, B.P.; Freedman, S.D. Cystic fibrosis. Lancet 2009, 373, 1891-1904.
6. Rowe, S.M.; Miller, S.; Sorscher, E.J. Cystic fibrosis. N. Engl. J. Med. 2005, 352, 1992-2001.
7. Kerem, E.; Corey, M.; Kerem, B.S.; Rommens, J.; Markiewicz, D.; Levison, H.; Tsui, L.C.; Durie, P. The relation between genotype and phenotype in cystic fibrosis-Analysis of the most common mutation (delta F508). N. Engl. J. Med. 1990, 323, 1517-1522.
8. Al-Turkmani, M.R.; Freedman, S.D.; Laposata, M. Fatty acid alterations and n-3 fatty acid supplementation in cystic fibrosis. Prostaglandins Leukot. Essent. Fat. Acids 2007, 77, 309-318.
9. Worgall, T.S. Lipid metabolism in cystic fibrosis. Curr. Opin. Clin. Nutr. Metab. Care 2009, 12, 105-109.
10. Strandvik, B. Fatty acid metabolism in cystic fibrosis. Prostaglandins Leukot. Essent. Fat. Acids 2010, 83, 121-129.
11. Nakamura, M.T.; Nara, T.Y. Essential fatty acid synthesis and its regulation in mammals. Prostaglandins Leukot. Essent. Fat. Acids 2003, 68, 145-150.
12. Nakamura, M.T.; Nara, T.Y. Gene regulation of mammalian desaturases. Biochem. Soc. Trans. 2002, 30, 1076-1079.
13. Kuo, P.T.; Huang, N.N.; Bassett, D.R. The fatty acid composition of the serum chylomicrons and adipose tissue of children with cystic fibrosis of the pancreas. J. Pediatr. 1962, 60, 394-403.
14. Rosenlund, M.L.; Kim, H.K.; Kritchevsky, D. Essential fatty acids in cystic fibrosis. Nature 1974, 251, 719.
15. Christophe, A.B.; Warwick, W.J.; Holman, R.T. Serum fatty acid profiles in cystic fibrosis patients and their parents. Lipids 1994, 29, 569-575.
16. Strandvik, B.; Gronowitz, E.; Enlund, F.; Martinsson, T.; Wahlstrom, J. Essential fatty acid deficiency in relation to genotype in patients with cystic fibrosis. J. Pediatr. 2001, 139, 650-655.
17. Olveira, G.; Dorado, A.; Olveira, C.; Padilla, A.; Rojo-Martinez, G.; Garcia-Escobar, E.; Gaspar, I.; Gonzalo, M.; Soriguer, F. Serum phospholipid fatty acid profile and dietary intake in an adult Mediterranean population with cystic fibrosis. Br. J. Nutr. 2006, 96, 343-349.
18. Maqbool, A.; Schall, J.I.; Garcia-Espana, J.F.; Zemel, B.S.; Strandvik, B.; Stallings, V.A. Serum linoleic acid status as a clinical indicator of essential fatty acid status in children with cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 2008, 47, 635-644.
19. Caren, R.; Corbo, L. Plasma fatty acids in pancreatic cystic fibrosis and liver disease. J. Clin. Endocrinol. Metab. 1966, 26, 470-477.
20. Hubbard, V.S.; Dunn, G.D.; di Sant'Agnese, P.A. Abnormal fatty-acid composition of plasma-lipids in cystic fibrosis. A primary or a secondary defect? Lancet 1977, 2, 1302-1304.
21. Lloyd-Still, J.D.; Johnson, S.B.; Holman, R.T. Essential fatty acid status in cystic fibrosis and the effects of safflower oil supplementation. Am. J. Clin. Nutr. 1981, 34, 1-7.
22. Rogiers, V.; Vercruysse, A.; Dab, I.; Baran, D. Abnormal fatty acid pattern of the plasma cholesterol ester fraction in cystic fibrosis patients with and without pancreatic insufficiency. Eur. J. Pediatr. 1983, 141, 39-42.
23. Farrell, P.M.; Mischler, E.H.; Engle, M.J.; Brown, D.J.; Lau, S.M. Fatty acid abnormalities in cystic fibrosis. Pediatr. Res. 1985, 19, 104-109.
24. Gibson, R.A.; Teubner, J.K.; Haines, K.; Cooper, D.M.; Davidson, G.P. Relationships between pulmonary function and plasma fatty acid levels in cystic fibrosis patients. J. Pediatr. Gastroenterol. Nutr. 1986, 5, 408-415.
25. Thompson, G.N. Relationships between essential fatty acid levels, pulmonary function and fat absorption in pre-adolescent cystic fibrosis children with good clinical scores. Eur. J. Pediatr. 1989, 148, 327-329.
26. Roulet, M.; Frascarolo, P.; Rappaz, I.; Pilet, M. Essential fatty acid deficiency in well nourished young cystic fibrosis patients. Eur. J. Pediatr. 1997, 156, 952-956.
27. Freedman, S.D.; Blanco, P.G.; Zaman, M.M.; Shea, J.C.; Ollero, M.; Hopper, I.K.; Weed, D.A.; Gelrud, A.; Regan, M.M.; Laposata, M.; et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N. Engl. J. Med. 2004, 350, 560-569.
28. Batal, I.; Ericsoussi, M.B.; Cluette-Brown, J.E.; O'Sullivan, B.P.; Freedman, S.D.; Savaille, J.E.; Laposata, M. Potential utility of plasma fatty acid analysis in the diagnosis of cystic fibrosis. Clin. Chem. 2007, 53, 78-84.
29. Aldamiz-Echevarria, L.; Prieto, J.A.; Andrade, F.; Elorz, J.; Sojo, A.; Lage, S.; Sanjurjo, P.; Vazquez, C.; Rodriguez-Soriano, J. Persistence of essential fatty acid deficiency in cystic fibrosis despite nutritional therapy. Pediatr. Res. 2009, 66, 585-589.
30. Hubbard, V.S.; Dunn, G.D. Fatty acid composition of erythrocyte phospholipids from patients with cystic fibrosis. Clin. Chim. Acta 1980, 102, 115-118.
31. Campbell, I.M.; Crozier, D.N.; Caton, R.B. Abnormal fatty acid composition and impaired oxygen supply in cystic fibrosis patients. Pediatrics 1976, 57, 480-486.
32. -/-mice. Proc. Natl. Acad. Sci. USA 1999, 96, 13995-14000.
33. -/-knockout mice. Metabolism 2006, 55, 1192-1200.
34. Mimoun, M.; Coste, T.C.; Lebacq, J.; Lebecque, P.; Wallemacq, P.; Leal, T.; Armand, M. Increased tissue arachidonic acid and reduced linoleic acid in a mouse model of cystic fibrosis are reversed by supplemental glycerophospholipids enriched in docosahexaenoic acid. J. Nutr. 2009, 139, 2358-2364.
35. Rajan, S.; Cacalano, G.; Bryan, R.; Ratner, A.J.; Sontich, C.U.; van Heerckeren, A.; Davis, P.; Prince, A. Pseudomonas aeruginosa induction of apoptosis in respiratory epithelial cells: Analysis of the effects of cystic fibrosis transmembrane conductance regulator dysfunction and bacterial virulence factors. Am. J. Respir. Cell Mol. Biol. 2000, 23, 304-312.
36. Zeitlin, P.L.; Lu, L.; Rhim, J.; Cutting, G.; Stetten, G.; Kieffer, K.A.; Craig, R.; Guggino, W.B. A cystic fibrosis bronchial epithelial cell line: Immortalization by adeno-12-SV40 infection. Am. J. Respir. Cell Mol. Biol. 1991, 4, 313-319.
37. Andersson, C.; Al-Turkmani, M.R.; Savaille, J.E.; Alturkmani, R.; Katrangi, W.; Cluette-Brown, J.E.; Zaman, M.M.; Laposata, M.; Freedman, S.D. Cell culture models demonstrate that CFTR dysfunction leads to defective fatty acid composition and metabolism. J. Lipid Res. 2008, 49, 1692-1700.
38. Al-Turkmani, M.R.; Andersson, C.; Alturkmani, R.; Katrangi, W.; Cluette-Brown, J.E.; Freedman, S.D.; Laposata, M. A mechanism accounting for the low cellular level of linoleic acid in cystic fibrosis and its reversal by DHA. J. Lipid Res. 2008, 49, 1946-1954.
39. Njoroge, S.W.; Seegmiller, A.C.; Katrangi, W.; Laposata, M. Increased Delta5- and Delta6-desaturase, cyclooxygenase-2, and lipoxygenase-5 expression and activity are associated with fatty acid and eicosanoid changes in cystic fibrosis. Biochim. Biophys. Acta 2011, 1811, 431-440.
40. Thomsen, K.F.; Laposata, M.; Njoroge, S.W.; Umunakwe, O.C.; Katrangi, W.; Seegmiller, A.C. Increased elongase 6 and Delta9-desaturase activity are associated with n-7 and n-9 fatty acid changes in cystic fibrosis. Lipids 2011, 46, 669-677.
41. Holman, R.T. The ratio of trienoic: Tetraenoic acids in tissue lipids as a measure of essential fatty acid requirement. J. Nutr. 1960, 70, 405-410.
42. Gilljam, H.; Strandvik, B.; Ellin, A.; Wiman, L.G. Increased mole fraction of arachidonic acid in bronchial phospholipids in patients with cystic fibrosis. Scand. J. Clin. Lab. Investig. 1986, 46, 511-518.
43. Njoroge, S.W.; Laposata, M.; Katrangi, W.; Seegmiller, A.C. DHA and EPA reverse cystic fibrosis-related FA abnormalities by suppressing FA desaturase expression and activity. J. Lipid Res. 2012, 53, 257-265.
44. Carlstedt-Duke, J.; Bronnegard, M.; Strandvik, B. Pathological regulation of arachidonic acid release in cystic fibrosis: The putative basic defect. Proc. Natl. Acad. Sci. USA 1986, 83, 9202-9206.
45. Levistre, R.; Lemnaouar, M.; Rybkine, T.; Bereziat, G.; Masliah, J. Increase of bradykinin-stimulated arachidonic acid release in a delta F508 cystic fibrosis epithelial cell line. Biochim. Biophys. Acta 1993, 1181, 233-239.
46. Berguerand, M.; Klapisz, E.; Thomas, G.; Humbert, L.; Jouniaux, A.M.; Olivier, J.L.; Bereziat, G.; Masliah, J. Differential stimulation of cytosolic phospholipase A2 by bradykinin in human cystic fibrosis cell lines. Am. J. Respir. Cell Mol. Biol. 1997, 17, 481-490.
47. Miele, L.; Cordella-Miele, E.; Xing, M.; Frizzell, R.; Mukherjee, A.B. Cystic fibrosis gene mutation (deltaF508) is associated with an intrinsic abnormality in Ca2+-induced arachidonic acid release by epithelial cells. DNA Cell Biol. 1997, 16, 749-759.
48. Dif, F.; Wu, Y.Z.; Burgel, P.R.; Ollero, M.; Leduc, D.; Aarbiou, J.; Borot, F.; Gacria-Verdugo, I.; Martin, C.; Chignard, M.; et al. Critical role of cytosolic phospholipase a2{alpha} in bronchial mucus hyper-secretion in CFTR-deficient mice. Eur. Respir. J. 2010, 36, 1120-1130.
49. Wada, M.; DeLong, C.J.; Hong, Y.H.; Rieke, C.J.; Song, I.; Sidhu, R.S.; Yuan, C.; Warnock, M.; Schmaier, A.H.; Yokoyama, C.; et al. Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J. Biol. Chem. 2007, 282, 22254-22266.
50. Hiltunen, J.K.; Karki, T.; Hassinen, I.E.; Osmundsen, H. beta-Oxidation of polyunsaturated fatty acids by rat liver peroxisomes. A role for 2,4-dienoyl-coenzyme A reductase in peroxisomal beta-oxidation. J. Biol. Chem. 1986, 261, 16484-16493.
51. Gronn, M.; Christensen, E.; Hagve, T.A.; Christophersen, B.O. Peroxisomal retroconversion of docosahexaenoic acid (22:6(n-3)) to eicosapentaenoic acid (20:5(n-3)) studied in isolated rat liver cells. Biochim. Biophys. Acta 1991, 1081, 85-91.
52. Brossard, N.; Croset, M.; Pachiaudi, C.; Riou, J.P.; Tayot, J.L.; Lagarde, M. Retroconversion and metabolism of [13C]22:6n-3 in humans and rats after intake of a single dose of [13C]22:6n-3-triacylglycerols. Am. J. Clin. Nutr. 1996, 64, 577-586.
53. Stark, K.D.; Holub, B.J. Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy. Am. J. Clin. Nutr. 2004, 79, 765-773.
54. Innis, S.M.; Davidson, A.G. Cystic fibrosis and nutrition: Linking phospholipids and essential fatty acids with thiol metabolism. Annu. Rev. Nutr. 2008, 28, 55-72.
55. 2+. FEBS J. 2013, 280, 4417-4429.
56. Carling, D. The AMP-activated protein kinase cascade-A unifying system for energy control. Trends Biochem. Sci. 2004, 29, 18-24.
57. Hardie, D.G. AMPK: A key regulator of energy balance in the single cell and the whole organism. Int. J. Obes. 2008, 32 (Suppl. 4), S7-S12.
58. Mihaylova, M.M.; Shaw, R.J. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 2011, 13, 1016-1023.
59. Hallows, K.R.; Fitch, A.C.; Richardson, C.A.; Reynolds, P.R.; Clancy, J.P.; Dagher, P.C.; Witters, L.A.; Kolls, J.K.; Pilewski, J.M. Up-regulation of AMP-activated kinase by dysfunctional cystic fibrosis transmembrane conductance regulator in cystic fibrosis airway epithelial cells mitigates excessive inflammation. J. Biol. Chem. 2006, 281, 4231-4241.
60. Umunakwe, O.C.; Seegmiller, A.C. Abnormal n-6 fatty acid metabolism in cystic fibrosis is caused by activation of AMP-activated protein kinase. J. Lipid Res. 2014, 55, 1489-1497.
61. Woods, A.; Johnstone, S.R.; Dickerson, K.; Leiper, F.C.; Fryer, L.G.; Neumann, D.; Schlattner, U.; Wallimann, T.; Carlson, M.; Carling, D. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr. Biol. 2003, 13, 2004-2008.
62. Hawley, S.A.; Pan, D.A.; Mustard, K.J.; Ross, L.; Bain, J.; Edelman, A.M.; Frenguelli, B.G.; Hardie, D.G. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab. 2005, 2, 9-19.
63. Antigny, F.; Norez, C.; Becq, F.; Vandebrouck, C. Calcium homeostasis is abnormal in cystic fibrosis airway epithelial cells but is normalized after rescue of F508del-CFTR. Cell Calcium 2008, 43, 175-183.
64. Martins, J.R.; Kongsuphol, P.; Sammels, E.; Dahimene, S.; Aldehni, F.; Clarke, L.A.; Schreiber, R.; de Smedt, H.; Amaral, M.D.; Kunzelmann, K. F508del-CFTR increases intracellular Ca(2+) signaling that causes enhanced calcium-dependent Cl(-) conductance in cystic fibrosis. Biochim. Biophys. Acta 2011, 1812, 1385-1392.
65. Tang, C.; Cho, H.P.; Nakamura, M.T.; Clarke, S.D. Regulation of human delta-6 desaturase gene transcription: Identification of a functional direct repeat-1 element. J. Lipid Res. 2003, 44, 686-695.
66. Matsuzaka, T.; Shimano, H.; Yahagi, N.; Amemiya-Kudo, M.; Yoshikawa, T.; Hasty, A.H.; Tamura, Y.; Osuga, J.; Okazaki, H.; Iizuka, Y.; et al. Dual regulation of mouse Delta(5)- and Delta(6)-desaturase gene expression by SREBP-1 and PPARalpha. J. Lipid Res. 2002, 43, 107-114.
67. Nara, T.Y.; He, W.S.; Tang, C.; Clarke, S.D.; Nakamura, M.T. The E-box like sterol regulatory element mediates the suppression of human Delta-6 desaturase gene by highly unsaturated fatty acids. Biochem. Biophys. Res. Commun. 2002, 296, 111-117.
68. Li, Y.; Xu, S.; Mihaylova, M.M.; Zheng, B.; Hou, X.; Jiang, B.; Park, O.; Luo, Z.; Lefai, E.; Shyy, J.Y.J.; et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab. 2011, 13, 376-388.
69. Vega, R.B.; Huss, J.M.; Kelly, D.P. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol. Cell. Biol. 2000, 20, 1868-1876.
70. Lee, W.J.; Kim, M.; Park, H.S.; Kim, H.S.; Jeon, M.J.; Oh, K.S.; Koh, E.H.; Won, J.C.; Kim, M.S.; Oh, G.T.; et al. AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPARalpha and PGC-1. Biochem. Biophys. Res. Commun. 2006, 340, 291-295.
71. Jager, S.; Handschin, C.; St-Pierre, J.; Spiegelman, B.M. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc. Natl. Acad. Sci. USA 2007, 104, 12017-12022.
72. McGee, S.L.; van Denderen, B.J.; Howlett, K.F.; Mollica, J.; Schertzer, J.D.; Kemp, B.E.; Hargreaves, M. AMP-activated protein kinase regulates GLUT4 transcription by phosphorylating histone deacetylase 5. Diabetes 2008, 57, 860-867.
73. Mihaylova, M.M.; Vasquez, D.S.; Ravnskjaer, K.; Denechaud, P.D.; Yu, R.T.; Alvarez, J.G.; Downes, M.; Evans, R.M.; Montminy, M.; Shaw, R.J. Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis. Cell 2011, 145, 607-621.
74. Bungard, D.; Fuerth, B.J.; Zeng, P.Y.; Faubert, B.; Maas, N.L.; Viollet, B.; Carling, D.; Thompson, C.B.; Jones, R.G.; Berger, S.L. Signaling kinase AMPK activates stress-promoted transcription via histone H2B phosphorylation. Science 2010, 329, 1201-1205.
75. Ollero, M.; Astarita, G.; Guerrera, I.C.; Sermet-Gaudelus, I.; Trudel, S.; Piomelli, D.; Edelman, A. Plasma lipidomics reveals potential prognostic signatures within a cohort of cystic fibrosis patients. J. Lipid Res. 2011, 52, 1011-1022.
76. Harper, T.B.; Chase, H.P.; Henson, J.; Henson, P.M. Essential fatty acid deficiency in the rabbit as a model of nutritional impairment in cystic fibrosis. In vitro and in vivo effects on lung defense mechanisms. Am. Rev. Respir. Dis. 1982, 126, 540-547.
77. Craig-Schmidt, M.C.; Faircloth, S.A.; Teer, P.A.; Weete, J.D.; Wu, C.Y. The essential fatty acid deficient chicken as a model for cystic fibrosis. Am. J. Clin. Nutr. 1986, 44, 816-824.
78. Lemen, R.J.; Gates, A.J.; Mathe, A.A.; Waring, W.W.; Hyman, A.L.; Kadowitz, P.D. Relationships among digital clubbing, disease severity, and serum prostaglandins F2alpha and E concentrations in cystic fibrosis patients. Am. Rev. Respir. Dis. 1978, 117, 639-646.
79. Rigas, B.; Korenberg, J.R.; Merrill, W.W.; Levine, L. Prostaglandins E2 and E2 alpha are elevated in saliva of cystic fibrosis patients. Am. J. Gastroenterol. 1989, 84, 1408-1412.
80. Strandvik, B.; Svensson, E.; Seyberth, H.W. Prostanoid biosynthesis in patients with cystic fibrosis. Prostaglandins Leukot. Essent. Fat. Acids 1996, 55, 419-425.
81. Chen, J.; Jiang, X.H.; Chen, H.; Guo, J.H.; Tsang, L.L.; Yu, M.K.; Xu, W.M.; Chan, H.C. CFTR negatively regulates cyclooxygenase-2-PGE(2) positive feedback loop in inflammation. J. Cell. Physiol. 2012, 227, 2759-2766.
82. Jabr, S.; Gartner, S.; Milne, G.L.; Roca-Ferrer, J.; Casas, J.; Moreno, A.; Gelpi, E.; Picado, C. Quantification of major urinary metabolites of PGE2 and PGD2 in cystic fibrosis: Correlation with disease severity. Prostaglandins Leukot. Essent. Fat. Acids 2013, 89, 121-126.
83. Lucidi, V.; Ciabattoni, G.; Bella, S.; Barnes, P.J.; Montuschi, P. Exhaled 8-isoprostane and prostaglandin E(2) in patients with stable and unstable cystic fibrosis. Free Radic. Biol. Med. 2008, 45, 913-919.
84. Sampson, A.P.; Spencer, D.A.; Green, C.P.; Piper, P.J.; Price, J.F. Leukotrienes in the sputum and urine of cystic fibrosis children. Br. J. Clin. Pharmacol. 1990, 30, 861-869.
85. Konstan, M.W.; Walenga, R.W.; Hilliard, K.A.; Hilliard, J.B. Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis. Am. Rev. Respir. Dis. 1993, 148, 896-901.
86. Reid, D.W.; Misso, N.; Aggarwal, S.; Thompson, P.J.; Walters, E.H. Oxidative stress and lipid-derived inflammatory mediators during acute exacerbations of cystic fibrosis. Respirology 2007, 12, 63-69.
87. Shimizu, T.; Hansson, G.C.; Strandvik, B. Defective inhibition by dexamethasone of leukotriene B4 and C4 production by leukocytes in patients with cystic fibrosis. Prostaglandins Leukot. Essent. Fat. Acids 1994, 51, 407-410.
88. Karp, C.L.; Flick, L.M.; Park, K.W.; Softic, S.; Greer, T.M.; Keledjian, R.; Yang, R.; Uddin, J.; Guggino, W.B.; Atabani, S.F.; et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat. Immunol. 2004, 5, 388-392.
89. Karp, C.L.; Flick, L.M.; Yang, R.; Uddin, J.; Petasis, N.A. Cystic fibrosis and lipoxins. Prostaglandins Leukot. Essent. Fat. Acids 2005, 73, 263-270.
90. Roca-Ferrer, J.; Pujols, L.; Gartner, S.; Moreno, A.; Pumarola, F.; Mullol, J.; Cobos, N.; Picado, C. Upregulation of COX-1 and COX-2 in nasal polyps in cystic fibrosis. Thorax 2006, 61, 592-596.
91. Owens, J.M.; Shroyer, K.R.; Kingdom, T.T. Expression of cyclooxygenase and lipoxygenase enzymes in sinonasal mucosa of patients with cystic fibrosis. Arch. Otolaryngol. Head Neck Surg. 2008, 134, 825-831.
92. Elizur, A.; Cannon, C.L.; Ferkol, T.W. Airway inflammation in cystic fibrosis. Chest 2008, 133, 489-495.
93. De Lisle, R.C.; Meldi, L.; Flynn, M.; Jansson, K. Altered eicosanoid metabolism in the cystic fibrosis mouse small intestine. J. Pediatr. Gastroenterol. Nutr. 2008, 47, 406-416.
94. De Lisle, R.C.; Sewell, R.; Meldi, L. Enteric circular muscle dysfunction in the cystic fibrosis mouse small intestine. Neurogastroenterol. Motil. 2010, 22, 341-e87.
95. Linsdell, P. Inhibition of cystic fibrosis transmembrane conductance regulator chloride channel currents by arachidonic acid. Can. J. Physiol. Pharmacol. 2000, 78, 490-499.
96. Li, Y.; Wang, W.; Parker, W.; Clancy, J.P. Adenosine regulation of cystic fibrosis transmembrane conductance regulator through prostenoids in airway epithelia. Am. J. Respir. Cell Mol. Biol. 2006, 34, 600-608.
97. Zhou, J.J.; Linsdell, P. Molecular mechanism of arachidonic acid inhibition of the CFTR chloride channel. Eur. J. Pharmacol. 2007, 563, 88-91.
98. Dutta, A.K.; Okada, Y.; Sabirov, R.Z. Regulation of an ATP-conductive large-conductance anion channel and swelling-induced ATP release by arachidonic acid. J. Physiol. 2002, 542, 803-816.
99. Wojewodka, G.; de Sanctis, J.B.; Radzioch, D. Ceramide in cystic fibrosis: A potential new target for therapeutic intervention. J. Lipids 2011, 2011, 674968.
100. Teichgräber, V.; Ulrich, M.; Endlich, N.; Riethmüller, J.; Wilker, B.; de Oliveira-Munding, C.C.; van Heeckeren, A.M.; Barr, M.L.; von Kürthy, G.; Schmid, K.W.; et al. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat. Med. 2008, 14, 382-391.
101. White, N.M.; Jiang, D.; Burgess, J.D.; Bederman, I.R.; Previs, S.F.; Kelley, T.J. Altered cholesterol homeostasis in cultured and in vivo models of cystic fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 292, L476-L486.
102. Snouwaert, J.N.; Brigman, K.K.; Latour, A.M.; Malouf, N.N.; Boucher, R.C.; Smithies, O.; Koller, B.H. An animal model for cystic fibrosis made by gene targeting. Science 1992, 257, 1083-1088.
103. Snouwaert, J.N.; Brigman, K.K.; Latour, A.M.; Iraj, E.; Schwab, U.; Gilmour, M.I.; Koller, B.H. A murine model of cystic fibrosis. Am. J. Respir. Crit. Care Med. 1995, 151, S59-S64.
104. -/-mice and the effect of docosahexaenoic acid. J. Appl. Physiol. 2002, 92, 2169-2176.
105. Beharry, S.; Ackerley, C.; Corey, M.; Kent, G.; Heng, Y.M.; Christensen, H.; Luk, C.; Yantiss, R.K.; Nasser, I.A.; Zaman, M.; et al. Long-term docosahexaenoic acid therapy in a congenic murine model of cystic fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 292, G839-G848.
106. Wagener, J.S.; Zemanick, E.T.; Sontag, M.K. Newborn screening for cystic fibrosis. Curr. Opin. Pediatr. 2012, 24, 329-335.
107. Legrys, V.A.; McColley, S.A.; Li, Z.; Farrell, P.M. The need for quality improvement in sweat testing infants after newborn screening for cystic fibrosis. J. Pediatr. 2010, 157, 1035-1037.
108. Shoki, A.H.; Mayer-Hamblett, N.; Wilcox, P.G.; Sin, D.D.; Quon, B.S. Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations. Chest 2013, 144, 1659-1670.
109. Witters, P.; Dupont, L.; Vermeulen, F.; Proesmans, M.; Cassiman, D.; Wallemacq, P.; de Boeck, K. Lung transplantation in cystic fibrosis normalizes essential fatty acid profiles. J. Cyst. Fibros. 2012, 12, 222-228.
110. Wojewodka, G.; de Sanctis, J.B.; Bernier, J.; Bérubé, J.; Ahlgren, H.G.; Gruber, J.; Landry, J.; Lands, L.C.; Nguyen, D.; Rousseau, S.; et al. Candidate markers associated with the probability of future pulmonary exacerbations in cystic fibrosis patients. PLoS One 2014, 9, e88567.
111. Borowitz, D.; Baker, R.D.; Stallings, V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 2002, 35, 246-259.
112. Smith, C.; Winn, A.; Seddon, P.; Ranganathan, S. A fat lot of good: Balance and trends in fat intake in children with cystic fibrosis. J. Cyst. Fibros. 2011, 11, 154-157.
113. Simopoulos, A.P. Overview of evolutionary aspects of omega 3 fatty acids in the diet. World Rev. Nutr. Diet. 1998, 83, 1-11.
114. Blasbalg, T.L.; Hibbeln, J.R.; Ramsden, C.E.; Majchrzak, S.F.; Rawlings, R.R. Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th century. Am. J. Clin. Nutr. 2011, 93, 950-962.
115. Katrangi, W.; Lawrenz, J.; Seegmiller, A.C.; Laposata, M. Interactions of linoleic and alpha-linolenic acids in the development of Fatty Acid alterations in cystic fibrosis. Lipids 2013, 48, 333-342.
116. -/-transgenic mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 2010, 299, L599-L606.
117. Chase, H.P.; DuPont, J. Abnormal levels of prostaglandins and fatty acids in blood of childredn with cystic fibrosis. Lancet 1976, 2, 236-238.
118. Van Egmond, A.W.; Kosorok, M.R.; Koscik, R.; Laxova, A.; Farrell, P.M. Effect of linoleic acid intake on growth of infants with cystic fibrosis. Am. J. Clin. Nutr. 1996, 63, 746-752.
119. Rosenlund, M.L.; Selekman, J.A.; Kim, H.K.; Kritchevsky, D. Dietary essential fatty acids in cystic fibrosis. Pediatrics 1977, 59, 428-432.
120. Mischler, E.H.; Parrell, S.W.; Farrell, P.M.; Raynor, W.J.; Lemen, R.J. Correction of linoleic acid deficiency in cystic fibrosis. Pediatr. Res. 1986, 20, 36-41.
121. Oliver, C.; Watson, H. Omega-3 fatty acids for cystic fibrosis. Cochrane Database Syst. Rev. 2013, 11, CD002201.
122. De Vizia, B.; Raia, V.; Spano, C.; Pavlidis, C.; Coruzzo, A.; Alessio, M. Effect of an 8-month treatment with omega-3 fatty acids (eicosapentaenoic and docosahexaenoic) in patients with cystic fibrosis. JPEN J. Parenter. Enter. Nutr. 2003, 27, 52-57.
123. Olveira, G.; Olveira, C.; Acosta, E.; Espildora, F.; Garrido-Sanchez, L.; Garcia-Escobar, E.; Rojo-Martinez, G.; Gonzalo, M.; Soriguer, F. Fatty acid supplements improve respiratory, inflammatory and nutritional parameters in adults with cystic fibrosis. Arch. Bronconeumol. 2010, 46, 70-77.
124. Leggieri, E.; de Biase, R.V.; Savi, D.; Zullo, S.; Halili, I.; Quattrucci, S. Clinical effects of diet supplementation with DHA in pediatric patients suffering from cystic fibrosis. Minerva Pediatr. 2013, 65, 389-398.